D nia is a common finding in the human immunodeficiency type 1 (HIV-1)-infected host.' Such cytopenia has been observed in the absence of drug therapy or opportunistic infection, which has led to suggestions that the AIDS virus itself might cause a reduction in hematopoietic progenitor Consequently, progenitor cells (identified by the surface expression of the CD34 molecule5), obtained from the bone marrow of infected individuals, have been examined for HIV-1 infection. These studies have shown conflicting results; some suggest that CD34' cells represent a source of HIV-1 infection-some suggest o t h e r~i s e .~.~ Recent studies have proposed that the dysregulation of hematopoiesis may relate to the infection of marrow stromal cells with HIV-1."
Such interactions between the virus and the host might affect not only normal hematopoiesis, but also the in vivo response of hematopoietic progenitors to growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF. Impairment of this response would have implications for gene-transfer-based approaches to HIV-1 disease. GM-and G-CSF have been used to mobilize peripheral blood progenitor cells (PBPC) in cancer patients, which then have been used for autologous hematopoietic reconstitution. ''-I4 Mobilized PBPC have proven to be good candidates for gene-transfer protocols because of the relative ease of collection of large numbers of cells and their rapid rate of engraftment.'"'' However, most data regarding the mobilization, transduction, and reconstitution of PBPC have been obtained from patients with cancer."-'5 More recently, recombinant growth factors have been used in healthy individuals to mobilize CD34+cells for potential application in allogeneic tran~plantation.'~.'' Although mobilized PBPC cells would be theoretically well suited for gene therapy protocols for the treatment of HIV-1 infection, it remains to be established that progenitor cells can be mobilized from HIV-1-infected individuals."
To determine whether such mobilization is feasible, we conducted a clinical study in which recombinant G-CSF was administered to asymptomatic, HIV-1 -seropositive adults for 6 consecutive days. Blood was collected daily for CD34' cell enumeration, and a leukapheresis was performed on day 6 to gauge the number of CD34+ cells collected and to obtain nantly myeloid-committed, but between 0.2% and 1.7% were primitive CD34'/CD38-progenitors. A median of 21.7% of the mobilized CD34+ cells were dimly positive for CD4. Consequently, CD34+-enriched cells were purified on the cell sorter (mean purity, 97.7% ? 2.4%; n = 7). and examined for HIV-1 DNA. Purified CD34+ cells from two of seven donors were polymerase chain reaction (PCR)-positive for HIV-1, but only from one of three samples from each donor. We conclude that G-CSF can safely mobilize CD34+ progenitor cells in HIV-1-infected subjects, and that these cells are suitable for consideration in gene-transfer strategies. sufficient CD34+ cells to analyze their phenotype and HIV-1 status. These analyses have provided information important to our understanding of the biology of the HIV-1 -infected host, and to the development of strategies for genetransfer-based therapies.
MATERIALS AND METHODS
Subject selection. The protocol was approved by the institutional review board of St Jude Children's Research Hospital. HIV-l-infected, asymptomatic adults were eligible for enrollment after giving informed consent. To be eligible, subjects had to be over the age of 18 years, have a positive Western blot for HIV-1, CLM' T-cell count between 200 and l,OOO/pL, hematocrit 2 30%, platelet count 2 75,00O/pL, AST and serum creatinine within normal limits, and adequate venous access for leukapheresis. Subjects were excluded from study if they had previous allergic responses to G-CSF, had had myeloid leukemia, were pregnant, or were currently receiving recombinant cytokines (G-CSF, GM-CSF, erythropoietin, or interferon). Individuals receiving antiretroviral therapy before enrollment continued it during the study period.
Subjects received 10 pg/kg/d of G-CSF (Neupogen; Amgen, Thousand Oaks, CA), not to exceed the recommended maximum of 480 pLpld. In practice, all donors received 480 pg/d of G-CSF starting on day 1, for 6 consecutive days. Subjects were evaluated by history and physical examination at entry, daily for 6 Study design.
days, and then on days 14 and 28. Blood for laboratory studies was obtained before the daily injection of G-CSF. Blood for complete blood cell counts (CBCs; Coulter, Hialeah, FL), viral antigen level, T-and B-cell analysis, and CD34' cell analysis was drawn on days 1,6,14, and 28. CBC was also measured daily during G-CSF administration. Serum viral antigen levels were determined by enzymelinked immunosorbent assay (ELISA) (Coulter, Miami, FL) of immune complex dissociated p24 antigen (ICD p24). G-CSF was to be withheld if the white blood cell (WBC) count on any day of injection was greater than 60,000 cellslpL. No donor reached this count, and all subjects were scheduled for leukapheresis on day 6. Mononuclear cells (MNC) were collected from 8 to 10 L of blood, and processed using the Fenwal CS-3000 Plus Blood Cell Separator (Fenwal Division, Baxter Healthcare, Deerefield, IL). Cells harvested by leukapheresis were maintained at room temperature, and transported to the laboratory within 30 minutes of collection.
The CD34+ cell frequency in peripheral blood was determined by staining leukocytes present in whole blood with (peridinin chlorophyll protein [PerCPI-, fluorescein isothiocyanate [FITC] -, or phycoerythrin-) conjugated monoclonal antibodies @Ab) directed against CD45, CD34, and CD14 (Becton Dickinson [BD] Immunocytometry Systems, San Jose, CA). On the first day of G-CSF, a 100-pL aliquot of peripheral blood was stained with I O pL of each mAb. After the first day, with the increase in the peripheral leukocyte count in response to G-CSF administration, 20 pL of each mAb was used to stain a 50-pL aliquot of blood, to maintain the same degree of CD45 fluorescence. After staining, erythrocytes were lysed (Easy-Lyse; Leinco Technologies, Ballwin, MO) and leukocytes were fixed in 0.5% paraformaldehyde. The six daily samples were batched and analyzed together to reduce interassay variability (having previously confirmed no loss of fluorescence over this time period). Two-color flow cytometry was performed on the FACScan (BD). MNC were identified using forward-and side-light scatter signals. Leukocytes were identified by the expression of CD45, and the frequency of CD34' cells was determined among this population. For each analysis, a minimum of 10,000 events was collected and analyzed. The absolute number of CD34' cells in the peripheral blood was calculated by multiplying the CD34+ cell frequency by the total daily leukocyte count.
Immunophenotypic analysis was performed on CD34-enriched cells derived from the leukapheresis product. Aliquots of 2 X 10' CD34-enriched cells were stained with directly conjugated mAb directed against CD45, CD34, CD14, CD38, CD8, CD4 (two anti-CD4 mAb were used one from BD and one from Immunotech, Westbrook, ME), and CD19, CD13, and CD33 (Dako, Glostrup, Denmark). Before staining, cells were incubated with mouse immunoglobulin G1 (IgG1; Southern Biotechnology Associates, Birmingham, AL) to block nonspecific binding sites. After staining, cells were fixed in 0.5% paraformaldehyde, stored overnight at 4"C, and run as noted previously on the FACScan (BD).
CD34' cells were enriched from the leukapheresis product with an avidin-biotin immunoaffinity column (CellPro, Bothell, WA). MNC were first isolated by density gradient separation using Lymphoprep solution (Nycomed, Oslo, Norway) according to the manufacturer's directions. MNC were counted and incubated with the provided biotinylated anti-CD34 mAb (12.8; CellPro) for 25 minutes at room temperature. After washing, cells were resuspended to 1 X lo8 cellslml, loaded onto the immunoaffinity column, and CD34-enriched cells collected according to the manufacturer's instructions. Approximately 4 million of the CD34-enriched cells were then incubated with FITC-conjugated anti-CD34 (HPCA-2; BD), fixed in 4% paraformaldehyde, and sorted on the BD FACStar Plus Cell Sorter to yield 2 to 3 aliquots of 5 X IO5 purified CD34' cells each. DNA was extracted from each aliquot of cells, and each was run separately for polymerase chain reaction CD34' cell puriJcation. (PCR) analysis. One tenth of the total volume of extracted DNA was submitted for PCR for DQa (the HLA locus encoding the LY chain of the class I1 glycoprotein). DNA template from the equivalence of 2.5 X IO5 cells was used in each HIV-1 PCR reaction.
Three primers (denoted A, B, and C; kindly provided by J.L. Hunvitz") were used in a nested fashion to amplify a 754-bp fragment of the envelope gene of HIV-1. The sensitivity of the nested PCR reaction was determined by amplifying 10-fold serial dilutions of 8E5/LAV cells in uninfected CEM cells. 8E5LAV cells are known to contain a single integrated copy of HIV-I proviral DNA.2" DNA from the equivalence of 2.5 X 105 CEM cells at each dilution was used in the HIV-1 PCR reaction. The PCR mixture contained 10 mmoVL Tris-HC1, pH 8.3, 50 mmol/L KCI, 1.5 mmol/ L MgCI2, 0.01% gelatin, 1 mmol/L each dNTP, 75 ng of each primer, and 2.5 to 5 U of Taq polymerase (Applied Biosystems, Foster City, CA). The first HIV-1 env PCR reaction was with primers A and B, and was amplified for 40 cycles of 1 minute at 95"C, 2 minutes at 50°C. and 3.5 minutes at 72°C. The second, nested reaction used 5 p L of the product of the first round of amplification with primers B and C, and was reamplified for 35 cycles of 1 minute at 95"C, 2 minutes at 50°C. and 3.5 minutes at 72°C. A primer pair (GH26/ GH27) amplifying a 242-bp region of the HLA-DQu locus21 was used to determine the quality of the extracted DNA, following the published conditions.z2 A 5-pL quantity of the PCR reaction was reamplified, using the same GH26IGH27 primers, to increase sensitivity. Amplified fragments were electrophoresed on ethidium bromide-containing agarose gels (2%) and visualized under UV light. These amplified products were authenticated to be HIV-I envelope sequences by sequence analysis of the cloned PCR products, following previously published methods."
The primers were as follows: A primer, CATGTTTATAATITGll-lTATTCTGCATGG; B primer, CCATGTGTAAAA-TTAACCCCACTCTGTG; C primer, TACAATITCTGGGTCCCCTC-CTGAGG, GH26 primer, GTGCTGCAGGTGTAAACITGTACCAG; GH27 primer, CACGGATCCGGTAGCAGCGGTAGTAGITG.
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RESULTS

Subjects.
Eight donors were enrolled in the study, and seven were leukapheresed. Donor 2 was not leukapheresed because of inadequate venous access on day 6 of G-CSF. Details regarding the eight subjects are given in Table 1 . All subjects developed bone pain and myalgias in response to G-CSF, and all were controlled with acetaminophen (except one individual who required oral narcotic analgesic). Pain did not preclude any donor from completing the study.
Viral antigen levels in response to G-CSF administration. Serum from days 1, 6, 14, and 28 was collected and batch Table l. analyzed for ICDp24 levels. Results are presented in Fig 1. To determine whether the antigen levels changed over time after the administration of G-CSF, we used a random coefficient growth curve model with intercept and slope. The results of the Wald-type chi-square testz3 failed to demonstrate an association between ICDp24 and the described time points after the administration of G-CSF (x2 = 34, P = S6).
The administration of G-CSF resulted in an abrupt increase in the leukocyte count in all eight subjects in the 24 hours following the first dose. Most of this increase was secondary to an increase in mature and band neutrophils. Substantial interindividual variation in the peak leukocyte value was noted (range, 17.7 to 43.3 x 103WBC/pL), with a median among the eight donors of 30.6 X lo3 WBCIpL. Following cessation of the G-CSF, the WBC count on day 14 was below baseline in six of eight subjects, but showed recovery toward baseline on day 28.
Lymphocyte response to G-CSF administration. Although the percent circulating lymphocytes decreased with G-CSF administration (concomitant with the increase in the percent circulating neutrophils), an increase in the absolute number of lymphocytes was observed. Both T and B lymphocytes contributed to this increase. Among the eight donors, there was a median increase in the number of CD3+ T cells by 1.5-fold, and a median increase in the number of CD19' B cells by twofold, between days 1 and 6. Following the discontinuation of G-CSF, the lymphocyte number decreased to below baseline values by day 14 in six of the eight donors. These values showed recovery toward baseline on day 28. To determine whether the changes in the absolute number of CD3+ T cells in HIV-1 -infected individuals reflected changes in both CD4' and CD8+ T-cell subsets, we measured the CD4:CD8 ratios among the eight donors. The mean CD4:CDS ratio before G-CSF administration (0.5 t O.l), was unchanged following 6 days of G-CSF (0.5 t O.l), and remained so on days 14 and 28. Thus, CD4+ and CD8+ T cells contributed proportionately to the changes in the CD3+ T-cell count. Analysis of daily blood samples demonstrates that G-CSF can mobiLeukocyte response to G-CSF administration.
CD34+ cell response to G-CSF administration.
lize CD34+ cells in the HIV-1 -infected individual. Although great variability in the absolute number of CD34' cells recruited was observed, all eight donors showed a response to growth factor administration. The kinetics of the CD34+ cell response was similar among the donors, with the peak CD34' cell response occurring on day 5 or day 6 (Fig 2) .
The median number of CD34+ cells in the peripheral blood before G-CSF administration was 3 cells/pL (range, 2 to 9) and increased to a median of 11 1 cells/pL at the peak of the response (range, 55 to 401). This resulted in an overall median increase of 37-fold between baseline and peak CD34' cell number present in the circulation. To determine whether the donor baseline CD4+ T-cell count affected the magnitude of the CD34+ cell response, we regressed the peak CD34' cell count on the initial CD4' T-cell count. The simple regression analysis suggested that the CD4' T-cell count does not have any significant effect on the peak of the CD34' cell response ( P = .16).
Analysis of CD34+ cells in the leukapheresis product. Seven donors were leukapheresed on day 6 of G-CSF. The volume of the leukapheresis product among the seven subjects averaged approximately 55 mL, and contained a median of 0.67% (range, 0.4% to 1.7%) CD34+ cells. Numbers of mononuclear and CD34+ cells in the leukapheresis product are summarized in Table 2 .
To characterize CD34+ progenitor cells mobilized to the peripheral blood, we enriched the cells on an immunoaffinity column. The purity of the CD34-enriched fraction averaged 70% t 7% CD34+ cells (n = 7), with an overall yield of 36% t 11% of the CD34' cells calculated to have been loaded on the column. The G-CSF-mobilized CD34+ cells uniformly coexpress low levels of the CD45 marker (Fig 3) , similar to marrow-derived CD34+ cells. 24 To estimate the proportion of early CD34TD38-progenitor cells in the G-CSF-mobilized population, three-color FACS analysis was performed using antibodies directed against CD34, CD45, and CD38 molecules. Between 0.2% and 1.7% of the G-CSF-mobilized cells are primitive CD34+ CD38-cells (Table 3 and Fig 3) , which approximates the level found in Analysis of CD34+ cells for coexpression of my- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From eloid-associated antigens (CDI 3 and CD33) demonstrated that the majority of G-CSF-recruited CD34' cells are committed to the myeloid lineage (Table 3 and Fig 3) , as is characteristic of PBPC." Mobilized CD34' cells were also examined for the expression of lymphocyte markers, including CD19, CD8, and CD4 (Table 3) . A median of 0.5% of mobilized CD34' cells coexpress the B-cell marker, CD19, a median of 4% (range, 1 .O% to 8.8%) coexpress the CD8 molecule, and a median of 21.7% (range, 6.8% to 27.9%) coexpress the CD4 molecule, although the CD4 fluorescence was dim (Fig 3) . CD4 coexpression was not a feature of the particular anti-CD4 mAb used, as the observation was consistent when either of two different mAb were used (data not shown).
PCR analysis qf sorted CD34' cells, mobilized in HIV-I-infected individimls. The expression of CD4 on the surface of some of the mobilized CD34' cells prompts the question of whether these cells are infected with HIV-I in the infected host. To address this, we purified populations of CD34' cells on the cell sorter, and analyzed DNA extracted from these populations for HIV-I by PCR. Sorted CD34' cells had a mean purity of 97.7% ? 2.4% (range, 92.9% to 99.3%). Peripheral blood MNC and CD34-cells from all seven donors were positive by PCR for HIV-I (data not shown). However, purified CD34' cell DNA from five of the seven donors was negative by PCR for HIV-I (Fig  4) . Sorted CD34' cells from two donors (nos. 4 and 7) were PCR-positive for HIV-I on analysis of the first aliquot of sorted cells. However, PCR analyses of second and third aliquots (obtained from the same sorting procedure, but different collection tubes) from these two donors were PCRnegative. 
DISCUSSION
This study demonstrates that CD34' cells can be safely mobilized to the peripheral blood of HIV-I -infected donors following the administration of G-CSF. That progenitor cells can be mobilized in individuals with CD4' T-cell counts greater than 2OO/pL provides some insight into the interaction between HIV-I and the hematopoietic system. While studies suggest that hematopoietic progenitors may be reduced in the infected individual' (because of direct infection or secondary to infection of hematopoietic regulatory cell^'"^'^), the response of CD34' progenitors to G-CSF is not impaired in the HIV-1 -infected individual. This is true even in our donors with lower CD4' T-cell counts. Indeed, the donor with the highest CD34' cell response had the third lowest baseline CD4' T-cell count (380 cells/pL). Moreover, the CD34' cell responses to G-CSF are preserved in HIV-1 -infected subjects in degrees remarkably similar to those described for uninfected, healthy donors. Interestingly, the magnitude of the CD34' cell response among our subjects was greater than that described in two studies of healthy donors receiving G-CSF.'"." It is possible that these higher values simply represent the spectrum of responses that will become more evident as greater numbers of donors are evaluated. Alternatively, they may reflect technical differences in determining the frequency of CD34' cells in the peripheral blood. If found to be a consistent feature of HIV-I -infected subjects, these increased responses may be a reflection of a system driven to cope with sustained lymphocyte destruction.
Once mobilized to the peripheral blood compartment, the CD34' cells from our subjects were easily collected via leukapheresis in numbers (median, 194 X IO"; n = 7) comparable to those of uninfected individuals (mean, 119 2 65 X IO"; n = 7).16 Although the number of mobilized CD34' cells that will achieve prompt engraftment is not precisely defined, between 0.5 and 5 X 10" cellskg of patient body weight has been suggested as a threshold range.''.2x The number of mobilized CD34' cells collected in our study would fall within this range. The composition of the mobilized CD34' cells was also similar to that described for cells mobilized from uninfected individuals, including the proportions of early CD34TD38-progenitor cells.'" Insofar as this phenotype reflects hematopoietic potential, G-CSFmobilized cells in the infected individual will likely have similar reconstitution capability as those mobilized from the uninfected host. It has been suggested that a higher proportion of early progenitors are present among cells mobilized with GM-CSF'"; however, we elected to use G-CSF because GM-CSF (and not G-CSF) has been reported to enhance HIV-1 production in monocyte cultures.'".'" However, neither cytokine has been associated with consistent alteration of viral expression in vivo."-" We observed no sustained increase in serum antigen levels in this study, despite an increase in the number of circulating T lymphocytes in response to G-CSF. It is interesting to note that proportional increases in both CD4' and CD8' T cells contributed to the increase in T-cell numbers in the HIV-I -infected individual, similar to the responses reported in uninfected cancer patients receiving G-CSF.) ' The preservation of the CD34' cell response to G-CSF in HIV-1 -infected individuals might not exclude the possibility that these cells are infected with HIV-I, especially given the expression of dim levels of surface CD4 by a fraction of the G-CSF-mobilized CD34' cells. CD34TD4' progenitor cells are not unique to the HIV-1-infected individual, and have been described in studies of murine and human hematopoietic progenitor cell^.^"'^ In our study, PCR of sorted For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 25,000 cells. Thus, fewer than 10 proviral copies were present in the 250,000 mobilized CD34+ cells analyzed from donors with negative HIV-1 PCR results. Two donors had a positive PCR on the first aliquot of sorted CD34+ cells, but had negative PCR signals from the next two aliquots of CD34+ cells collected from the same sort. Each PCR was performed on 250,000 CD34' cells, with purities of 98.3% and 99.2% (donors 4 and 7, respectively). That only one of three samples was positive suggests that either a very small proportion of CD34' cells was infected (since the positive signal was not detected in the other two samples with 250,000 CD34' cells), or that a small number of contaminating CD4' cells was present in the positive samples. Serial dilutions of CD4+ T cells from donors 4 and 7 demonstrated that as few as 625 or 1,250 CD4+ T cells, respectively, could be con .stently detected in a population of 250,000 cells using our nested PCR technique. Perhaps such small numbers of CD4' T cells were present in the first aliquot of sorted cells collected from these two donors. The results of this study are similar to recent studies of marrow CD34+ cells from HIV-1 -infected individuals: and are consistent with the notion that CD34+ progenitor cells are not infected with HIV-1. Thus, G-CSF can safely mobilize CD34' progenitor cells in the HIV-1 -infected individual, and these cells represent an appropriate target for gene-transfer studies in the infected individual.
